Up-Front ASCT Overcomes the Survival Benefit Provided by HDAC-Based Induction Regimens in Mantle Cell Lymphoma: Data from a Real-Life and Long-Term Cohort.

J Luís Alberto de Pádua Covas LageMarcela do Vale EliasCadiele Oliana ReichertHebert Fabrício CullerFábio Alessandro de FreitasRenata de Oliveira CostaVanderson Geraldo RochaSheila Aparecida Coelho da SiqueiraJuliana Pereira

Published in: Cancers (2023)

In the largest Latin American cohort of MCL patients, we confirmed the OS benefit promoted by up-front consolidation with ASCT in young and fit patients, regardless of the intensity of the immunochemotherapy regimen used in the pre-ASCT induction. Although HDAC-based regimens were not associated with an unequivocal increase in OS for ASCT-eligible patients, it was associated with higher ORR and lower rates of early relapses for the whole cohort.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
prognostic factors
peritoneal dialysis
patient reported outcomes
electronic health record